MedPath

To see the effect of resveratrol and copper on outcome of death in patients with blood cancer admitted to Intensive Care Unit with fever and infection.

Not Applicable
Conditions
Health Condition 1: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue
Registration Number
CTRI/2020/03/024286
Lead Sponsor
TRAC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Age 18 -70 years

2. Hemato-lymphoid malignancy

3. Febrile neutropenia with expected duration of neutropenia >7 days

4. Need of ICU admission

Exclusion Criteria

1.History of Resveratrol and/or copper intake in dietary supplements in last 3 week

2.Patient admitted after cardiopulmonary resuscitation

3.Patients on warfarin

4.Underlying advance malignancy with no treatment option

5.Chronic renal failure with GFR <30 ml/min

6.Chronic liver dysfunction/cirrhosis

7.Pregnancy (urinary pregnancy kit for females of reproductive age group)

8.Known case of HIV/AIDS.

9.Moribund patient unlikely to survive for >48 hours at the time of screening as judged by the treating intensivist based on the presence of severe multi-organ dysfunction and shock despite resuscitation at the time of screening as assessed by any of the following parameters (not limited to):

ï?¯ Inability to maintain MAP >65 mm Hg on doses of noradrenaline or adrenaline exceeding 0.66 mic/kg/min or

ï?¯ Inability to maintain MAP >65 mm Hg on combination of vasopressin with either noradrenaline or adrenaline

ï?¯ Severe lactic acidosis (pH <7.15, lactate >8 mmol/L) in spite of fluid resuscitation, vasopressors and ventilator support.

ï?¯ The ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2 to FiO2 or PF ratio) <= 100.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath